S-1/A: Starton Holdings Files S-1/A for NASDAQ IPO to Fund Cancer Therapies

Sentiment:

Initial Public Offering Registration Statement (S-1/A) 13 March 2026 5:25 PM

Clinical-stage biotechnology company Starton Holdings, Inc. files an amended S-1 registration statement for its initial public offering of 6,666,667 shares of common stock, aiming to raise approximately $37.2 million to advance its cancer therapies.

Delay expectedThe commercialization of STAR-LLD is planned for after Revlimid's IP protection expires in April 2028, indicating a delay in market entry for the lead product.The STAR-OLZ product candidate program is on hold while the company focuses on its lead programs, STAR-LLD.The FDA placed a clinical hold on a proposed Phase 1b study for STAR-LLD-SC in first-line MM patients, requiring protocol resubmission and further guidance, which caused a delay in that specific trial's initiation.The drug regulatory approval processes are described as 'lengthy, time consuming and inherently unpredictable,' with no guarantee that FDA approval will be obtained in the anticipated timeframes or ever.

Capital raiseThe filing is an S-1/A registration statement for an initial public offering (IPO) of 6,666,667 shares of common stock, with an estimated offering price between $5.00 and $7.00 per share, aiming to raise approximately $37.2 million in net proceeds.The company explicitly states it 'will require substantial additional capital to finance our operations' beyond the IPO proceeds to complete Phase 3 clinical studies and seek NDAs for commercialization of STAR-LLD-OCR and other future product candidates.The company expects to finance future cash needs through 'public or private equity or debt financings or other capital sources, including potential collaborations, licenses, and other similar arrangements.'Management loans totaling $2.0 million from the CEO were received in September and November 2025 to fund operations.

Summary

Starton Holdings, Inc. is a clinical-stage biotechnology company focused on improving standard-of-care cancer therapies using proprietary continuous delivery technology systems.
The lead development programs, STAR-LLD, are continuous delivery systems of lenalidomide (generic Revlimid) for multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).
The company is developing both subcutaneous (STAR-LLD-SC) and oral controlled release (STAR-LLD-OCR) formulations in parallel.
A Phase 1b clinical program for STAR-LLD-SC in relapsed/refractory multiple myeloma (RRMM) completed with positive interim top-line data, showing 100% of 6 patients achieved partial response (PR) or better, with no severe hematologic toxicity.
A Phase 2a study for STAR-LLD-SC in RRMM is currently underway.
The STAR-LLD-OCR oral formulation is awaiting regulatory approval to initiate a human healthy volunteer bioavailability study, with a Phase 2b RRMM study planned for Q2/2027.
Investigator Initiated Trials (IIT) for STAR-LLD-SC with CAR-T therapies in MM and lymphoma are planned to start at the end of Q2/2026.
Commercialization of STAR-LLD-OCR in high-risk RRMM is estimated around 2030, after Revlimid's patent expiration in Q1/2028.
Commercialization of STAR-LLD-OCR in CLL is estimated around 2033.
Another product candidate, STAR-OLZ (olanzapine transdermal delivery for chemotherapy-induced nausea and vomiting), is currently on hold.
The company incurred net losses of $9.5 million for the year ended March 31, 2025, and $11.1 million for the nine months ended December 31, 2025.
A working capital deficit of $3.3 million was reported as of December 31, 2025.
The independent registered public accounting firm's report contains an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern.
A material weakness in internal control over financial reporting was identified, related to the lack of accounting resources.
The initial public offering aims to raise approximately $37.2 million (at the $6.00/share midpoint) from 6,666,667 shares, with an option for underwriters to purchase an additional 1,000,000 shares.
Net proceeds from the IPO are expected to fund the Phase 2 MM trial, initiate the Phase 1 CLL study for STAR-LLD-OCR, initiate IIT studies with STAR-LLD-SC in CAR-T, and provide working capital for at least one year.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing with cautious optimism. While the clinical data for STAR-LLD is promising, particularly the safety and efficacy signals in early trials and favorable pharmacokinetic profile, the company faces significant financial challenges, including a going concern warning and the need for substantial future capital. The long development timelines and intense competition in oncology temper the positive clinical updates.

Positives

Proprietary platform of continuous delivery technology systems for FDA-approved active ingredients, potentially offering enhanced outcomes or new indications.
Lead programs (STAR-LLD) target hematologic malignancies (blood cancers) with significant unmet medical needs.
Positive interim top-line data from Phase 1b clinical program for STAR-LLD-SC in RRMM, showing 100% of 6 patients achieved partial response (PR) or better, with no severe (grade >2) hematologic toxicity.
FDA agreed to allow initiation of a Phase 2a clinical study in RRMM for STAR-LLD-SC.
Preclinical efficacy study in a MM mouse model demonstrated statistically significant enhanced efficacy for STAR-LLD continuous infusion versus standard of care lenalidomide, with an 81% reduction in tumor volume and 20% of animals tumor-free at 100 days in the 144 mcg/day cohort.
A Phase 1 healthy volunteer study demonstrated STAR-LLD-SC was greater than 92% bioavailable across all dosage groups compared to oral Revlimid, with significantly lower Cmax (16-fold) and AUC (2-fold) on a mg-to-mg basis, suggesting improved tolerability.
Intellectual property position provides protection until at least 2040 for STAR-LLD.
CLL is an orphan disease, and any approved drug for CLL will qualify for seven years of orphan drug exclusivity, along with potential tax credits and waived application fees.
Potential for accelerated approval designation for MM and CLL indications.
The management team possesses extensive experience in the pharmaceutical industry.
The company has raised approximately $54 million from common stock issuance to date.

Negatives

The company is a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale, and may never achieve or maintain profitability.
Incurred significant net losses: $9.5 million for the year ended March 31, 2025, and $11.1 million for the nine months ended December 31, 2025.
Reported a working capital deficit of $3.3 million as of December 31, 2025.
The independent registered public accounting firm's report expresses substantial doubt about the company's ability to continue as a going concern.
A material weakness in internal control over financial reporting was identified due to a lack of accounting resources.
Substantial additional capital will be required beyond the IPO proceeds to complete Phase 3 clinical studies and seek NDAs for commercialization of STAR-LLD-OCR and other pipeline programs.
The STAR-OLZ product candidate program is currently on hold.
Revlimid (lenalidomide) is under IP protection until April 2028 in the U.S., delaying the commercialization of STAR-LLD until after this date.
Lenalidomide currently carries a black box warning for CLL and is contraindicated for use in CLL outside of clinical trials.
Previous CLL studies with the originator drug (Revlimid) showed increased drug-related deaths and no significant improvement in overall survival in some trials, leading to study stoppage.
The company faces intense competition from other development-stage and large pharmaceutical companies.
Reliance on third-party suppliers for raw materials and contract manufacturers for production beyond Phase 1 introduces supply chain risks.
The company currently lacks its own sales, marketing, or distribution capabilities.
A small number of existing stockholders own a large percentage of voting stock (management holds 17.3% pre-offering, 14.1% post-offering), potentially limiting the influence of new shareholders.
The common stock price may be volatile, and an active, liquid trading market may not develop.
Investors' interests will be diluted by the IPO and any future equity issuances.
Delaware law and corporate charter provisions could make mergers or takeovers difficult.

Risks

The company is a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale, and may never achieve or maintain profitability.
The independent registered public accounting firm's report contains an explanatory paragraph that expresses substantial doubt about the company's ability to continue as a going concern.
A material weakness in internal control over financial reporting was identified, and if remediation is not effective or additional weaknesses are found, financial reporting may be inaccurate or untimely.
Even if this offering is successful, substantial additional capital will be required to finance operations, and failure to obtain it could force delays, reductions, or termination of development programs or commercialization efforts.
Inability to develop or commercialize product candidates on a timely or cost-effective basis, including STAR-LLD and future pipeline programs, would adversely affect operating results.
Intense competition from other development-stage companies and large pharmaceutical companies could limit or make market objectives obsolete.
Future success depends on the ability to attract and retain key employees and consultants.
Dependence on the ability to protect intellectual property and proprietary rights, including in international markets, and risk of inability to keep such rights confidential or adequately protected.
Competitors or other third parties may allege infringement or misappropriation of their intellectual property, leading to substantial and uncertain litigation expenses.
Increasing dependence on information technology, with systems and infrastructure facing cybersecurity and data leakage risks.
The ability to use net operating loss carryforwards to offset future taxable income may be subject to certain limitations.
The company and its manufacturing partners are subject to extensive governmental regulation, and noncompliance may result in fines, product seizures, recalls, injunctive actions, or criminal prosecutions.
The drug regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable, potentially harming the business if regulatory approval is not obtained.
Results of preclinical studies or early clinical trials may not be indicative of results obtained in later trials, and the FDA may not accept new drug applications even after all planned clinical trials are completed.
Clinical trial failures or delays could result in increased costs and prevent or delay regulatory approval and product sales; difficulty enrolling patients could also delay development.
Products or product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label.
Approved product candidates may cause serious adverse events or undesirable side effects, potentially leading to market withdrawal, safety warnings, or limited sales.
The market opportunities for STAR-LLD may be smaller than anticipated.
Successful commercialization depends in part on governmental authorities and health insurers establishing adequate coverage, reimbursement levels, and pricing policies.
Even if approved, product candidates may fail to achieve market acceptance by physicians, patients, third-party payors, or others in the medical community.
Inability to establish sales, marketing, and distribution capabilities, either independently or through collaborations, may hinder commercialization success.
A small number of existing stockholders own a large percentage of voting stock, resulting in minimal influence for other shareholders over decisions.
The common stock price may be volatile, leading to potential loss of investment.
An active, liquid trading market for common stock may not develop, limiting the ability to sell shares.
Investors' interests in common stock will be diluted, and net book value per share may suffer dilution if additional options, shares, or warrants are issued to finance operations.
Delaware law and provisions in charter documents could make a merger, tender offer, or proxy contest difficult, potentially depressing the potential trading price of common stock.
Compliance with public company obligations will increase costs and require additional management resources, with a risk of failure to comply.
If the common stock is delisted from NASDAQ Capital Market, U.S. broker-dealers may be discouraged from effecting transactions due to 'penny stock' rules.
Changes in patent laws or patent jurisprudence could diminish the value of patents, impairing the ability to protect products and product candidates.
Failure to obtain patent term extension in the U.S. under the Hatch-Waxman Act and in foreign countries under similar legislation could materially harm the business.
The company and its service providers may be subject to a variety of privacy and data security laws and contractual obligations, which could increase compliance costs and lead to significant liability, fines, or penalties.
Enacted and future healthcare legislation (e.g., ACA, IRA) may increase the difficulty and cost of obtaining marketing approval and commercializing product candidates, and may affect pricing.
Government price reporting obligations are complex and subject to review and challenge, potentially leading to civil and criminal sanctions.
Drug pedigree laws (e.g., DSCSA) impose obligations on the commercial product supply chain, requiring extensive tracking systems and compliance.

Future Outlook

The company expects to announce a second program in formulation development within the next 12 to 18 months. It intends to commercialize STAR-LLD-OCR in high-risk RRMM around 2030 and in CLL around 2033, following Revlimid's patent expiration in Q1/2028. Commercialization of STAR-LLD-SC in combination with CAR-T cell therapies in lymphoma and multiple myeloma is estimated for 2030 and 2031, respectively. The company plans to establish its own commercial operations in the U.S. and seek distributor/licensee arrangements globally. The net proceeds from this IPO, combined with existing cash, are projected to fund operations through 2026, including the Phase 2 MM trial and Phase 1 CLL study for STAR-LLD-OCR, but substantial additional capital will be required for Phase 3 clinical studies and commercialization. The company also anticipates increased general and administrative costs as a public company and will continue efforts to remediate its material weakness in internal control over financial reporting.

Management Comments

"We are a clinical-stage biotechnology company focused on improving standard-of-care therapies for people with cancer through application of our proprietary platform of delivery technology systems."
"We believe our proprietary continuous delivery platform can potentially increase efficacy of approved drugs, make them more tolerable, and expand their potential use."
"We believe the pharmacokinetic representation in the figure is an important point of differentiation for Starton and encompasses the rationale of a lower total overall exposure at the target pharmacodynamic blood level creating a unique precision-targeted delivery."
"We expect to continue to incur net losses and expect significant cash outflows for the foreseeable future."
"We intend to use a majority of the net proceeds from the offering to support product development activities for STAR-LLD-SC and STAR-LLD-OCR our leading drug delivery candidates; and for working capital and other general corporate purposes, including payment of certain outstanding trade payables and amounts due and owing to related parties."
"We believe that establishing our own commercial operations in our core strategic market (the U.S.) strengthens our ability to negotiate with strategic participants in the market and is an important component of our strategy."
"We also believe that through our strategic relationships with commercial payors and medical organizations we can accelerate the size and development of the market at a marginal incremental cost, and therefore, we may be able to achieve faster and higher market penetrations when compared to commercializing the products ourselves."

Industry Context

StockSavvy.ai notes that Starton Holdings operates in the highly competitive and rapidly evolving biotechnology and pharmaceutical industry, specifically targeting hematologic malignancies. The strategy of improving existing FDA-approved drugs through novel continuous delivery systems (505(b)(2) pathway) is a common approach to potentially reduce development timelines and costs, though it still requires full clinical programs for new indications or superiority claims. The focus on lenalidomide, a cornerstone IMiD with global revenues of $12.8 billion in 2022, positions Starton to potentially capture a segment of a well-established market by addressing tolerability and expanding indications, particularly in areas like CLL where lenalidomide currently has a black box warning. The planned IITs with CAR-T therapies also align with the growing trend of combination immunotherapies in oncology.

Comparison to Industry Standards

The 100% partial response or better rate in the Phase 1b RRMM study (N=6) for STAR-LLD-SC is a strong early signal, but it is based on a very small sample size. Standard lenalidomide-based triplet regimens in RRMM typically show overall response rates (ORR) ranging from 60-80% in larger Phase 3 trials, with varying complete response (CR) rates.
The reported 'no severe (grade >2) hematologic toxicity' for STAR-LLD-SC is a key differentiator, as originator lenalidomide is known for significant hematologic toxicities, with Grade 3-4 low platelet and neutrophil counts potentially reaching a combined 70%.
The preclinical mouse model showing an 81% reduction in tumor volume and 20% tumor-free animals at 100 days for STAR-LLD versus a 483% increase for standard of care is a compelling preclinical result, suggesting potential superiority in efficacy and tolerability.
The Phase 1 bioavailability study demonstrating 16-fold lower Cmax and 2-fold lower AUC for STAR-LLD-SC compared to oral Revlimid on a mg-to-mg basis represents a significant pharmacokinetic improvement, directly addressing the known toxicity profile of lenalidomide which is linked to high Cmax and AUC. This could lead to better tolerability and compliance, a critical factor in chronic cancer therapies.
The company's reliance on the 505(b)(2) regulatory pathway is a standard industry strategy for drug repurposing or new formulations of approved drugs, aiming for a potentially faster and less costly approval process by leveraging existing safety and efficacy data. However, the need for full clinical development programs (Phase 1, 2, 3) for new indications or superiority claims means the path is still lengthy and expensive, similar to a traditional NDA for a new chemical entity in terms of clinical burden.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Structure	The board of directors is comprised of five directors and is divided into three classes with staggered three-year terms, with one class elected each year.	Upon consummation of this offering	This classified board structure may delay or prevent changes in control of the company.
Committee Establishment	The board has established an audit committee, a compensation committee, and a nominating and governance committee.	Prior to the completion of this offering	Enhances corporate oversight and compliance with NASDAQ listing rules.
Director Independence	Eric Baum, Moses Dodo, Nitin Kaushal, and Roy Waldron have been determined to be independent directors under NASDAQ Listing Rules and SEC Rule 10A-3(b)(1).	Upon completion of this offering	Ensures compliance with regulatory requirements for board independence and strengthens oversight.
Audit Committee Financial Expert	Nitin Kaushal has been determined to be an audit committee financial expert as defined in Item 407(d)(5) of Regulation S-K.	Upon completion of this offering	Provides specialized financial expertise to the audit committee, enhancing financial reporting oversight.
Code of Business Conduct and Ethics	Adopted a written code of business conduct and ethics applicable to all directors, officers, and employees.	Upon closing of this offering	Establishes ethical standards and promotes a culture of compliance within the company.
Director Liability and Indemnification	Certificate of incorporation and bylaws limit directors' liability and provide for indemnification to the fullest extent permitted under Delaware General Corporation Law (DGCL).	Immediately prior to the completion of this offering	Aims to attract and retain qualified directors and officers by reducing personal liability risks, but does not cover liabilities under federal securities laws.
Exclusive Forum Provision	Certificate of incorporation and bylaws designate the Court of Chancery of the State of Delaware as the exclusive forum for certain disputes, and federal district courts for Securities Act claims.	Immediately prior to the completion of this offering	May limit stockholders' ability to choose a favorable judicial forum and could discourage certain lawsuits, potentially increasing costs for stockholders not residing in Delaware.
Charter Amendment Thresholds	Amendment of certain charter provisions requires approval by a stockholder vote of at least 66 2/3% of the voting power of the then outstanding voting stock.	Immediately prior to the completion of this offering	Makes it more difficult for stockholders to effect certain changes to the company's governance structure.
Non-Employee Director Compensation	Non-employee directors are awarded a baseline amount of annual stock option grants based on a formula (33,333 shares for board service, 5,000 for committee chair, 2,500 for committee member).	Ongoing (fiscal year ended March 31, 2025)	Aligns directors' interests with stockholders through equity incentives, but also represents a compensation expense.

Legal Proceedings

There are currently no pending or threatened legal proceedings or claims against the company that are likely to have a material adverse effect on its business, operating results, financial condition, or cash flows.

Related Party Transactions

Research Services Agreement with Transdermal Research Pharma Laboratories LLC (the Lab), an affiliate of principal stockholder Fotios Plakogiannis, for $90,000 per month. The agreement was terminated effective November 30, 2025, with approximately $2.3 million in deferred fees outstanding as of December 31, 2025.
Assignment Agreement with Alpha to Omega Pharmaceutical Consultants, Inc. (AOPC), also affiliated with Fotios Plakogiannis, for transdermal patch technology. The company issued 555,556 shares (post-split) in October 2018 and 877,198 shares (post-split) in February 2021 for achieving milestones. As of December 31, 2025, AOPC had been issued a total of 197,368 shares (post-split) with an aggregate fair value of $1.0 million for milestones.
Consulting Agreement with Kenneth Anderson, MD (Scientific Advisory Board member) for an annual retainer of $60,000, plus a bonus of $1,000,000 in common stock for each New Drug Approval in MM indication. Also awarded $500,000 of options for director service.
Consulting Agreement with Mohamad Hussein, MD (Scientific Advisory Board member) for an annual consulting fee of $250,000 plus an hourly fee for services exceeding 50 hours per month.
Consulting Agreement with Asher Chanan-Khan, M.B.B.S., MD (Scientific Advisory Board member) for an annual consulting fee of $60,000, plus a bonus of $1,000,000 in common stock for each New Drug Approval for STAR-LLD-OCR in CLL. Also awarded $500,000 of options for director service.
Consulting Agreement with Kiriakos Capital Ltd., an affiliate of Kiriakos Perperidis (a >5% shareholder), for investor relations and financing consulting services at $6,000 per month. $90,000 of deferred fees remain due as of December 31, 2025.
Management loans from CEO Pedro Lichtinger Waisman totaling $2,000,000 (First Tranche $1M on Sep 4, 2025; Second Tranche $1M on Nov 19, 2025) at 12% interest per annum, with $2,000,000 outstanding as of December 31, 2025. Previous loans from Pedro Lichtinger Waisman, Fotios Plakogiannis, and Kiriakos Perperidis were repaid by conversion into shares of common stock.
Deferred consulting and service fees totaling $3,333,682 are owed to various related parties, including Pedro Lichtinger Waisman ($360,383), Transdermal Research Pharma Laboratories LLC ($2,301,911), Kiriakos Capital Ltd. ($90,000), Andy Rensink and ATR Consultants LLC ($192,013), Asher Chanan-Khan, MD ($189,000), Kenneth Anderson, MD ($47,250), and Mohamad Hussein, MD ($153,125).

Stakeholder Impact

Shareholders: Potential for significant dilution from the IPO and future capital raises, but also potential for substantial value appreciation if product candidates achieve regulatory approval and commercial success. However, the 'going concern' warning and stock price volatility present considerable risks.
Employees: Continued employment and potential for equity-based compensation are tied to the company's ability to secure funding and advance its programs. Job security could be at risk if funding is not obtained or development programs fail.
Customers (future patients): The development of continuous delivery systems for lenalidomide and other active ingredients aims to provide improved standard-of-care therapies for cancer, potentially offering enhanced efficacy and reduced side effects, leading to better patient outcomes.
Suppliers and Creditors: The company's working capital deficit and 'going concern' status indicate a risk of delayed payments or non-payment. Successful commercialization could lead to increased business, but current financial health poses a risk.
Management: Key management personnel have significant influence due to concentrated stock ownership and stand to benefit substantially from successful product development and commercialization through salaries, bonuses, and equity awards. They also bear the primary responsibility for navigating the company's financial and operational challenges.

Next Steps

Complete the initial public offering and list shares on NASDAQ Capital Market under the symbol STA.
Advance Phase 1 clinical development of STAR-LLD-OCR in CLL.
Advance Phase 2 clinical development of STAR-LLD-(SC and OCR) in high-risk RRMM.
Fund and initiate several Investigator Initiated Trials (IIT) studies of STAR-LLD-SC in combination with CAR-T cell therapies in RRMM and lymphoma (expected end of Q2/2026).
Obtain regulatory approval to initiate a human healthy volunteer bioavailability study for STAR-LLD-OCR.
Initiate a Phase 2b RRMM study for STAR-LLD-OCR in Q2/2027.
Identify and develop other promising drug candidates for the continuous delivery platform.
Conduct full clinical development programs (Phase 1, Phase 2, and Phase 3) for product candidates.
Develop manufacturing processes and chemistry, manufacturing, and control (CMC) for Oral Controlled Release (OCR), Transdermal Delivery Systems (TDS), and Subcutaneous (SC) delivery systems.
Seek accelerated approval designation for MM and CLL indications.
Establish commercial operations in the U.S. market and distributor networks/licensee arrangements globally, post-regulatory approval.
Remediate the identified material weakness in internal control over financial reporting.
Continue to raise substantial additional capital to fund operations beyond 2026, including Phase 3 trials and commercialization.

Key Dates

Date	Description
2017-02-07	Starton Therapeutics, Inc. (Canada), the predecessor reporting entity, was formed.
2017-11-16	Entered into an assignment agreement with Alpha to Omega Pharmaceutical Consultants, Inc. (AOPC) for transdermal patch technology.
2018-10-01	Entered into a Consulting Agreement with Kiriakos Capital.
2018-10-24	Issued 5 million shares of common stock to an AOPC designee for achieving transdermal patch feasibility milestones.
2019-09-09	Entered into a new 6-year research service agreement with Transdermal Research Pharma Laboratories LLC (the Lab).
2019-09-09	Entered into a new assignment agreement with AOPC, replacing the original.
2019-12-18	Amended the AOPC assignment agreement to issue shares for additional transdermal formulations.
2020-01-13	Entered into a 10-year lease for lab and pilot manufacturing space and office space.
2020-01-23	Entered into an asset purchase agreement with Pike Therapeutics to sell one of its transdermal patch technologies.
2020-06-11	Entered into a Consulting Agreement with Mohamad Hussein, MD.
2020-07-31	Entered into a Consulting Agreement with Kenneth Anderson, MD.
2020-12-23	Submitted a pre-IND request to the FDA to discuss the path forward for STAR-LLD-SC.
2021-02-17	Issued 877,198 shares of common stock to AOPC for achieving an additional transdermal formulation milestone.
2021-02-10	Entered into an exclusive development and commercial license agreement with Haisco Pharmaceutical Group Co., Ltd. for STAR-OLZ in Mainland China.
2021-04-28	Entered into a Consulting Agreement with Asher Chanan-Khan, M.B.B.S., MD.
2023-04-27	Pedro Lichtinger Waisman's Executive Employment Agreement became effective.
2023-05-12	Paid SPAC Advisory Partners LLC an advisory fee of $200,000.
2023-05-31	Received FDA authorization to begin the Phase 1b clinical program in the U.S. with the initiation of the STAR-LLD-MM-023 protocol.
2023-06-05	Initiation of the Phase 1b study start-up process began.
2023-12-04	Entered into an agreement with an advisor for general business development and financial advisory services.
2024-04-02	Executed an engagement letter with Titan Advisory Services LLC for go-public strategy and investor relations.
2024-06-01	Announced interim, top-line data from the Phase 1b study for STAR-LLD-SC.
2024-07-09	Entered into an agreement with Titan Partners Group LLC as exclusive financial advisor and underwriter for an IPO (later terminated).
2024-10-10	Issued 83,334 shares of common stock for services to an advisor.
2024-11-13	Entered into a second amendment to the Asset Purchase Agreement with Pike Therapeutics, receiving $3.0 million in Pike shares.
2024-11-19	CBIZ CPAs P.C. acquired the attest business of Marcum LLP.
2024-11-29	Chinese patent 114901287B for Treatment of vomiting and nausea with minimum dose of olanzapine issued.
2024-12-19	The asset sale to Pike Therapeutics closed, and assets were transferred.
2025-01-01	Phase 1b end of study meeting with the FDA took place.
2025-04-01	An abstract with Phase 1b results was presented at AACR.
2025-05-13	The 2025 Starton Holdings, Inc. Omnibus Incentive Plan was approved by stockholders.
2025-05-27	Executed the termination of the research service agreement with Transdermal Research Pharma Laboratories LLC, effective November 30, 2025.
2025-07-16	Mexican patent 425779 for Continuous delivery of lenalidomide and other immunomodulatory agents issued.
2025-08-06	Consummated a private placement, issuing and selling 1,182,218 shares of common stock for approximately $6.6 million.
2025-08-12	US patent 12,383,510 for Treatment of vomiting and nausea with minimum dose of olanzapine issued.
2025-08-19	US patent 12,390,457 for Stable solutions of immunomodulatory imide compounds for parenteral use issued.
2025-09-02	The agreement with Titan Partners Group LLC was terminated.
2025-09-04	Entered into a loan agreement with CEO Pedro Lichtinger Waisman for up to $2,000,000 (First Tranche of $1,000,000 advanced).
2025-10-30	Entered into a 12-month agreement with Revere Securities LLC, appointing them as exclusive underwriter for the IPO.
2025-11-05	Corporate reorganization completed, and new Bylaws became effective.
2025-11-06	Redomiciliation and reorganization completed, making Starton Holdings Inc. the new registrant.
2025-11-19	Second Tranche of $1,000,000 loan from Pedro Lichtinger Waisman advanced.
2025-11-24	Stockholders approved a proposal granting the Board of Directors discretion to effect a 1-for-3 reverse stock split.
2025-11-24	Consummated a private placement, issuing and selling 364,773 shares of common stock for approximately $1.8 million.
2025-11-27	Australian patent 2020363285 for Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents issued.
2025-11-30	Research service agreement with Transdermal Research Pharma Laboratories LLC terminated.
2025-12-09	A 1-for-3 reverse stock split was effected.
2026-01-01	Human healthy volunteer study for STAR-LLD-OCR initiated.
2026-02-12	Issued 1,044,020 shares of common stock at $5.58 per share for gross proceeds of approximately $5.8 million.
2026-02-26	Received proceeds from the sale of common stock subscriptions for 7,530 shares at $6.64 per share, totaling $50,000.
2026-03-13	Filing date of the S-1/A registration statement.
2026-06-30	Investigator Initiated Trials (IIT) studies with STAR-LLD-SC in CAR-T therapies expected to start.
2026-09-01	Monthly interest-only payments for the Amortized Portion of the First Tranche of the management loan end.
2026-11-01	Monthly interest-only payments for the Amortized Portion of the Second Tranche of the management loan end.
2027-04-01	Phase 2b RRMM study for STAR-LLD-OCR planned to begin.
2028-04-01	Revlimid IP protection is expected to expire in the U.S.
2028-09-01	First Tranche of the management loan matures.
2028-11-01	Second Tranche of the management loan matures.
2030-01-01	Estimated commercialization of STAR-LLD-OCR in high-risk RRMM.
2030-04-15	Lease for corporate headquarters and lab facilities expires.
2030-01-01	Estimated commercialization of STAR-LLD-SC in combination with CAR-T cell therapies in lymphoma.
2031-01-01	Estimated commercialization of STAR-LLD-SC in combination with CAR-T cell therapies in multiple myeloma.
2033-01-01	Estimated commercialization of STAR-LLD-OCR in CLL.
2037-01-01	State net operating loss carryforwards and U.S. research tax credit carryforwards begin to expire.
2040-04-01	US patent 11,197,852, Mexican patent 425779, and Australian patent 2020363285 for STAR-LLD expire.
2041-01-01	Chinese patent 114901287B and US patent 12,383,510 for STAR-OLZ expire.
2042-03-01	US patent 12,390,457 for stable immunomodulatory imide compounds solutions expires.

Recommendation

hold

The company presents a high-risk, high-reward investment profile. While the early clinical data for STAR-LLD is promising, particularly regarding improved tolerability and efficacy signals, the company is still in early clinical stages with no approved products and faces significant financial challenges, including a going concern warning and a substantial need for future capital. The long development timelines and intense competition in oncology suggest a 'hold' recommendation for seasoned investors, advising caution due to the inherent uncertainties and financial risks, while acknowledging the potential for future upside if clinical milestones are met and funding is secured.

Keywords

Biotechnology, Clinical-stage, Cancer therapy, Hematologic malignancies, Multiple myeloma, Chronic lymphocytic leukemia, Lenalidomide, Revlimid, Continuous drug delivery, Subcutaneous infusion, Oral controlled release, CAR-T therapy, FDA approval, IPO, Pharmaceutical development, Oncology, Drug delivery systems, STAR-LLD, STAR-OLZ, Olanzapine, Chemotherapy-induced nausea and vomiting, Risk factors, Corporate governance, Financial reporting, NASDAQ Capital Market

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.